Visit PubMed to view Dr. Larry Corey's full publication record.
A blog series discussing the evolving science and policy of COVID-19 vaccines, led by internationally renowned experts in vaccine development, Dr. Larry Corey of the Univeristy of Washington/Fred Hutch, and Dr. Chris Beyrer of Johns Hopkins University.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.
Haeseleer F, Eichholz K, Tareen SU, Iwamoto N, Roederer M, Kirchhoff F, Park H, Okoye AA, Corey L. Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell. AIDS Res Hum Retroviruses. 2020 Dec;36(12):998-1009.
McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, Bossard EL, Phasouk K, Ford ES, Diem K, Klock AM, Jerome KR, Corey L. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. medRxiv. 2020 Jul 21:2020.07.19.20157198.
Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020 May 29;368(6494):948-950.
Randhawa AK, Fisher LH, Greninger AL, Li SS, Andriesen J, Corey L, Jerome KR. Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. JAMA. 2020 Jun 9;323(22):2334-2336.
Hosseinipour MC, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G, Sebe M, Maganga L, Herce ME, deCamp AC, Marshall K, Dintwe O, Andersen-Nissen E, Tomaras GD, Mkhize N, Morris L, Jensen R, Miner MD, Pantaleo G, Ding S, Van Der Meeren O, Barnett SW, McElrath MJ, Corey L, Kublin JG. Phase 1 HIV vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C Env protein. Clin Infect Dis. 2020 Jan 4. pii: ciz1239.
Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 Sep 18;11(510).
Li AZ, Corey L, Zhu J. Random-Reaction-Seed Method for Automated Identification of Neurite Elongation and Branching. Sci Rep. 2019 Feb 27;9(1):2908.
Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle DM, Picker LJ, Burgener A, Corey L, Miller CJ. Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. J Virol. 2019 Jan 4;93(2).
Ford ES, Magaret AS, Spak CW, Selke S, Kuntz S, Corey L, Wald A. Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. AIDS. 2018 Nov 13;32(17):2525-2531.
Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. J Infect Dis. 2018 Oct 20;218(11):1691-1699.
Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren W, Vazquez J, O'Day DR, Glass IA, Knipe DM, Wald A, Corey L, Zhu J. Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. J Exp Med. 2017 Aug 7;214(8):2315-2329.
Corey L, Gray GE. Preventing acquisition of HIV is the only path to an AIDS-free generation. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3798-3800.
Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, Magaret AS, Johnston C, Wald A, Zhu J, Corey L, Koelle DM. Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunol. 2017 Sep;10(5):1259-1269.
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H. Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial. JAMA. 2016 Dec 20;316(23):2495-2503.
Milman N, Zhu J, Johnston C, Cheng A, Magaret A, Koelle DM, Huang ML, Jin L, Klock A, Layton ED, Corey L. In situ detection of regulatory T cells in human genital HSV-2 reactivation and their influence on spontaneous HSV-2 reactivation. J Infect Dis. 2016 Jul 1;214(1):23-31.
Corey L, Gilbert P, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune Correlates of Vaccine Protection Against HIV-1 Acquisition: A Review. Sci Transl Med. 2015 Oct 21;7(310):310rv7.
Reprint | Full Text
Christine M. Posavad, Lin Zhao, Dawn E. Mueller, Claire E. Stevens, Meei Li Huang, Anna Wald and Lawrence Corey. Persistence of mucosal T cell responses to herpes simplex virus type 2 (HSV-2) in the female genital tract. Mucosal Immun. 2015 Jan;8(1):115-26. PMC4263695
Johnston C, Zhu J, Jing L, Laing K, McClurkan C, Klock A, Diem K, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, and Corey L. Virologic and immunologic evidence of multifocal genital herpes simplex virus type 2 infection. J Virol. 2014 May;88(9):4921-31.
Schiffer JT and Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med. 2013 Mar 6;19(3):280-8. NIHMSID559213
Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Obemichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L. Rapid Localized Spread and Immunologic Containment of Herpes Simplex Virus-2 in the Human Genital Tract. eLife. 2013;2:e00288.
Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, Jin L, Diem K, Koelle DM, Wald A, Robins H, Corey L. Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature. 2013 May 23;497(7450):494-7.
Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials. Lancet. 2012 Feb 18;379(9816):641-7. PMC3420069
Peng T, Zhu J, Phasouk K, Koelle D, Wald A and Corey L. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection. J Virol. 2012 Oct;86(19):10587-96. PMC3457322
Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. PMC2973882
Peng T, Zhu J, Klock A, Phasouk K, Huang ML, Koelle DM, Wald A, Corey L. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol. 2009 Dec;83(23):12559-68. PMC2786730
Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, Wald A, Corey L. Frequent Release of Low Amounts of Herpes Simplex Virus From Neurons: Results of a Mathematical Model. Sci Transl Med. 2009 Nov 1;1(7):7ra16. PMC2818652
Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009 Aug; 15(8):886-92. PMC2723183